We compared the effects of the cationic ionophore, monensin, on the synthesis, maturation and release of vesicular stomatitis virus (VSV) in cultures of Chinese hamster ovary (CHO) cells and the monensin-resistant clone, MonR-31. Our results depended on the dose and time of the addition of monensin to the infected cells, from 1 h prior to VSV infection to 1 h after infection. VSV production was more resistant in MonR-31 than in CHO cells when the ionophore was added 1 h prior to VSV infection. Monensin added 1 h after VSV infection showed the opposite phenomenon; release of virus particles into the medium was 10-to 105-fold less in MonR-31 cells than in CHO cells, and the intracellular virus number in the resistant cells was onethird to one-fourth of that in the parental CHO cells.
Some enveloped animal viruses such as Semliki Forest virus (SFV), vesicular stomatitis virus (VSV) and influenza virus enter their host cells through endocytosis in cytoplasmic vacuoles, the "receptosome" or "endosome" (6, 16, 43) . Monensin, a monovalent ionophoric antibiotic, has been useful in studies on a number of processes in which bioactive molecules cross membranes ; it inhibits pinocytosis (42), the recycling of low density lipoprotein receptor (3) , the transport of toxins into the cytoplasm (15) , the transport of membrane glycoproteins to the cell surface (34) , the penetration of VSV and SFV into cultured cells (17, 31) , the processing of albumin (20) and the glycosylation of secretory proteins (21, 27, 34) . Because the Golgi apparatus has compartments specific for such post-translational modification of peptides as proteolysis, glycosylation and sulfation (4, 28) , a primary site of monensin action is believed to be at this apparatus. Consistent with this supposition, Tartakoff and Vassalli (37, 38) found Golgi structures with dilated and dispersed cisternae as well as the accumulation of newly synthesized proteins in monensin-treated mammalian cells.
We recently isolated monensin-resistant clones from a Chinese hamster ovary (CHO) cell line that showed aberrant binding and the endocytosis of a toxin of Ricinus communis, ricin, as well as insulin (25, 26, 30) . We here compare the effect of monensin on the production of VSV in the monensin-resistant clone and in the parental CHO cell line when monensin is added before or after virus infection. One would expect that a mutant resistant to an antibiotic might function better in all respects compared to the wild type when the antibiotic is present. Contrary to expectation, monensin showed greater inhibition of the translation and the release of VSV proteins in the monensin-resistant clone than in the parental clone when it was added after VSV infection. We therefore studied the biochemical properties of the virus produced in the monensin-treated resistant clone when the ionophore was added after VSV infection. MATERIALS AND METHODS (38) . We therefore compared the ultrastructures in CHO and MonR-31 cells treated with 10-5 M monensin.
RESULTS

Comparison of the monensin effect on the morphological structures of CHO and MonR-31 cells. Monensin brings about the characteristic dilation of Golgi elements in various cells
In comparison with untreated CHO or MonR-31 cells ( Fig. 1A synthesized on membrane-bound polysomes (9) . In the Golgi apparatus, after transport from the rough endoplasmic reticulum, the high mannose-type oligosaccharides of G protein undergo a series of modifications, producing a complex form (12, 28) .
In studies of the modification of carbohydrate chains of the high mannose-type to the complex type, endo H has been the analytical tool used to differentiate the carbohydrates moieties; it cleaves between two proximal N-acetylglucosamine residues of the high mannose type, but the complex form is resistant to this enzyme (44). Fig. 2A shows that the newly synthesized G in VSV-infected CHO and MonR-31 cells was sensitive to endo H, from which we infer that it contains the high mannose sugar structure. We also found that G protein was cleaved to two forms that differ in molecular weight after endo H digestion, even in the presence of six different protease inhibitors ( Fig. 2A) .
In the absence of the ionophore, the G protein in both cell lines became completely resistant to endo H after 1 h ( Fig. 2A) . In the presence of 10-5 M monensin, greater inhibition of G, N and M syntheses took place in MonR-31 than in CHO, whereas G protein was still sensitive to endo H after a 1 h chase. Subsequently, the molecular weight of the G protein became the smaller value (Gt) that had been found after the chase (Fig. 2B ). Patterns very similar to Fig. 2B were seen when both cell lines were treated with 10-6 M monensin (Ono, M., data not shown).
To test whether the greater inhibitory effect of monensin on VSV-related proteins is due to decreased synthesis of viral specific RNA, VSV-dependent RNA was followed in both cell lines in the absence and presence of 10-5 M monensin.
Time kinetics of VSV-dependent RNA synthesis showed the initial onset of RNA synthesis in both CHO and MonR-31 cells to begin 1 h after, infection with VSV ( Fig. 3) . This VSV-dependent RNA synthesis in both cell types was inhibited 15 to 20 % by 4 to 5 h after VSV infection with 10-5 M monensin (Fig. 3 ). This contrasts sharply with the data shown in Table 2 and Fig. 2 , in which there is greater inhibition of VSV production as well as VSV protein synthesis in the VSV-infected resistant clone.
Effect of monensin on the structural integrity of viral G proteins. Because shows that VSV release from infected Mona-31 cells is more fully inhibited by monensin than is CHO, one might ask whether the properties of viral proteins are similar for the VSV in CHO and Mona-31 cells when monensin is present. VSV particles labeled with [35S]methionine isolated from cultured medium and those obtained from intracellular locations by cell lysis followed by immunoprecipitation with anti-VSV antibody were analyzed by SDS-PAGE and autoradiographed. PAGE patterns showed G, N and M proteins in the VSV particles from both the intracellular and the extracellular locations in CHO and Mona-31 cells (Fig. 4) . The reduced molecular weight of M protein in VSV particles released from CHO or Mona-31 cells into the medium, truncated M (Mt), is seen in Fig. 4 . Compared with the G, N and M proteins of the intracellular VSV, a much reduced content of viral proteins was present in extracellular VSV particles when 10-5 or 10-4 M monensin was used. In good accord with the results of infective plaque assays (Table  2) , much less VSV was released from monensin-treated MonR-31 cells than from the monensin-treated parental cells. We also found that the size of the VSV glycoprotein G of the intracellular VSV particles in both monensin-treated CHO and MonR-31 cells was smaller (Gt in Fig. 4 ). Endoglycosidase H (endo H), a specific endoglycosidase for high mannose, but not for mature, complex type, did not cleave the Gt molecule (Fig. 4) .
One or two molecules of palmitic acid are attached covalently to the polypeptide chain of the viral glycoprotein G (32) . The attachment of this fatty acid is believed to be important for transport from the Golgi apparatus to the plasma membrane where the assembly and budding of viral particles take place (44). A differential effect of a high dose of monensin on VSV production was shown for CHO and MonR-31 ( Fig. 4 and Table 2 ). We therefore examined whether this differential effect of the drug on the two cell lines was due to an altered palmitic acid attachment to the G protein ( Fig. 5 ). Only truncated G, Gt, appeared in VSV particles from intracellular and extracellular locations in monensin-treated CHO and MonR-31 cells, but comparable [3H]palmitic acid binding to Gt was observed ( Fig. 5 ). Longer exposure to X-ray film than the time shown in Fig. 5 shows that there is binding of palmitic acid to the Gt protein in the presence of 10-5 M monensin. We have asked whether the diminished molecular weight of Gt is due to structural alteration of the oligosaccharide moiety of the protein molecule per se. An addition of fucose to the glycoprotein makes the moiety resistant to endo H digestion (36) .
[3H]fucose also was incorporated into the Gt in both the CHO and MonR-31 cells in the presence of 10-6 M or 10-5 monensin (Fig. 6 ). But, treatment of the Gt protein with fucosidase and endo H did not decrease its molecular size (Ono, M., data not shown). We therefore tested the effect of neuraminidase (sialidase) treatment on G and Gt. Treatment of G with sialidase decreased the molecular weight of the protein derived from the VSV made in CHO or MonR-31 cells, whereas treatment of the Gt of the VSV made in 10-5 M monensin-treated CHO or MonR-31 cells did not (Fig. 7) . Gt thus appears to carry less sialic acid than the normal G molecule. The diminished size of G free of oligosaccharide also was shown when cells were treated with tunicamycin ( Fig. 7) . These data suggest that Gt carries an incomplete complex type of oligosaccharide that contains a fucose moiety with less sialic acid than normal G. compartment called an "endosome" or "receptosome" (6, 16, 43) . Endocytic vesicles are acidified rapidly prior to the fusion of these vesicles with lysosomes (33, 40) , and SFV or influenza virus starts to penetrate from the acidic prelysosomal vacuoles (16, 43) . Monensin is reported to raise the pH of the endocytotic vesicles in cultured mouse fibroblasts (19) . Selection of clones resistant to this ionophoric antibiotic is a powerful tool with which to isolate mutants that have altered receptor or endocytosis activities.
The monensin-resistant clones isolated from mutagenized CHO cells have shown aberrant responses to ricin and insulin; defective endocytosis of ricin and decreased affinity for insulin binding (26, 30) . Also, two membrane proteins of the parental CHO line are more highly phosphorylated than those of the monensin-resistant clones (25) . We also isolated a monensin-resistant clone from mouse Balb/3T3 cells. The mouse clone shows reduced receptor-mediated endocytosis of low density lipoprotein (39) and reduced sensitivity to VSV infection (24) .
The yield of VSV in the monensin-resistant clone is 100-fold less than that of the parental Balb/3T3 cell line in the absence of monensin (24) . Unlike the resistant mouse clone, the yield of VSV particles in MonR-31 was similar to that in CHO cells in the absence of monensin. The altered site in MonR-31 cells thus appears to differ from that in the monensin-resistant mouse clone. The monensin-resistant clone derived from CHO cells shows about a 5-fold higher resistance to monensin (26) . More greatly reduced production of VSV in CHO than in MonR-31 cells is found when monensin is added before viral infection. VSV, or Semliki Forest virus, enters mammalian cells through an acidic compartment, the endosome (6), whereas monensin raises the pH in the endosome (19) . The greater reduction of virus yield in CHO cells may be due to a more rapid change in endosomal pH in CHO cells prior to virus infection than there is in the resistant cells.
In contrast, when monensin is added after infection the effect on the VSV production process is surprisingly different. The study reported here shows a greater inhibition of VSV protein synthesis by monensin in MonR-31 cells than in CHO cells when monensin is added after infection. The amount of VSV particles that accumulate in the monensin-treated resistant clone are several fold less than in the monensintreated CHO cells. We found a 100-fold greater reduction of VSV secretion into the medium from MonR-31 cells treated with 10-4 M monensin than we found from CHO cells.
Glycosylation and the transport of viral membrane glycoproteins of VSV are modulated by monensin (1, 2, 7) . VSV proteins might be inadequately processed in the resistant clone in the presence of monensin, resulting in poor secretion from the resistant cells. The results reported here, however, suggest that the biochemical properties of glycoprotein G are similar for both monensin-treated CHO and MonR-31 cells ; the VSV protein bearing a smaller G, Gt, even though fucose was added to the Gt at comparable rates for both cell lines and Gt bears less sialic acid than normal G in both virus-infected cell lines.
Nonglycosylated proteins inserted in VSV as transmembrane proteins result in the production of infective virus particles, when cultured in the presence of tunicamycin (5, 29) . Also, there are known temperature-sensitive mutants of VSV whose transport of G protein to the cell surface is blocked at a non-permissive temperature (44), and palmitic acid fails to bind to the G of the mutant VSV. But, apparent binding of palmitic acid to G and Gt in the VSV produced in monensin-treated or untreated CHO or MonR-31 cells was observed; therefore, reduced exocytosis of the VSV from monensin-treated MonR-31 cells may not be due to grossly altered palmitic acid binding or the glycosylation of G protein.
No qualitative changes in G and the other viral proteins were found in CHO or MonR-31 cells in the presence of monensin. The cellular component(s) that function in the processing of viral proteins may not be changed in the monensin-treated resistant clone. Our previous study showed low endocytosis of ricin (26) and a low affinity for insulin (30) in MonR-31 cells. Also, it has been suggested that the number of low density lipoprotein receptors is decreased in MonR-31 cells (Tomita, K., Ono, M., Yoshida, T., Kuwano, M., unpublished data).
Any membraneous component altered in the resistant clone might specifically affect the release or synthesis of virus-related proteins in the presence of monensin. Cellular lesion might affect viral formation and release of VSV in at least two ways : (1) Certain cellular glycolipids or enzymes have been suggested to be incorporated into VSV particles (41). This specific incorporation of cell surface proteins into budding VSV particles has been shown by Lodish and Porter (15) ; two host cell surface proteins with 110K and 20K molecular weights being incorporated into VSV virions.
(2) The cellular factor specifically altered in the resistant clone might affect viral release and viral synthesis. Further study is needed to determine the mutation site in the monensin-resistant MonR-31 clone.
